

Phoebe Xi
Counsel | Patent Attorney
Email: ForeignPatent@changtsi.com | Phone: +86 10 88369999

Phoebe Xi is a Patent Counsel and the leader of the Bio-Chemistry Group at Chang Tsi & Partners. With a career in patent law that began in 2011, she has developed deep expertise in the field and has been an invaluable asset to our firm since 2014.

Phoebe' s experience spans a wide range of patent-related activities, including drafting and prosecuting patent applications, handling challenges and defenses in reexamination proceedings before the CNIPA, representing clients in oral hearings in invalidation proceedings, managing patent portfolios, and developing strategic patent filing plans. She also handles plant variety protection, from filing variety right applications with the Ministry of Agriculture and Rural Affairs through to DUS (distinctness, uniformity and stability) testing.

Her professional expertise covers biomedicine and health, chemistry and materials science, environment and energy technology, and agriculture and food technology. Phoebe excels in specialized fields such as clean energy, small molecule and macromolecular drugs, diagnostics, and food-related technologies, demonstrating her proficiency in these areas. Prior to joining Chang Tsi, Phoebe gained valuable experience working for three years in the R&D department of one of China' s leading energy companies, further enriching her knowledge and understanding of the industry. Over her career she has handled more than 1,000 patent applications for clients in biopharmaceuticals, bioagriculture and food technology.

Technical Field

- Pharmaceutical Research and Development
- Genetic Technology
- Biotechnology
- Organic Chemistry

- Inorganic Chemistry
- Polymer Chemistry
- Environmental Chemistry
- Renewable Energy
- Energy-Saving Technology
- Environmental Protection
- Water Treatment Technology
- Bioagriculture
- Food Science
- Aquaculture

Years with IP Matters

- 2011 until now

Professional Experience

- Counsel, Patent Attorney, Chang Tsi & Partners, 2014 - Present
- Patent Attorney, Jeekai & Partners, 2011 - 2014
- R&D engineer, Patent Principal, Xinao Group, 2008 - 2011

Representative Matters

- [2018] | Compound patent: Where the examiner intended to reject a compound patent application for a biopharmaceutical client, Xi proved the unexpected treatment effect obtained by the compound in the application and secured the grant. On the strength of that result, the client transferred its remaining applications from other firms to Chang Tsi.
- [2020] | Chemical patent reexamination: Acting as the lead attorney for all patent matters of a well-known American chemical company, Xi repeatedly obtained decisions revoking the rejections in reexamination proceedings, maintaining the validity of the client’s patents.
- [2022] | Patentability of diagnostic methods: The examiner objected that the claims were directed to non-patentable subject matter, and the technical features could not be redrafted as a medical use claim. Drawing on a High Court judgment, Xi proposed alternative amendments and argued the point in the response; the application was granted.
- [2019] | Markush claims: Where the examiner required a substantial narrowing of the Markush claims, Xi responded to the Office Action, established that the scope claimed was reasonable and secured for the client a scope broader than expected.
- [2024] | Crystal form patent application: The examiner held that the improvement of the claimed crystal form over the known compounds was foreseeable to the skilled person, and on that basis denied inventive step. Xi proved markedly improved crystallinity, solubility and low hygroscopicity over the free base form, submitting a number of granted patents as supporting references; the examiner accepted that the crystal form achieved an unexpected technical effect and the application was granted.

Rankings and Recognition

- "Notable Practitioner" by MIP IP STARS 2024-2026

Education

- Master of Science in Physical Chemistry, Taiyuan University of Technology (2008)
- Bachelor of Bioengineering, Inner Mongolia University of Technology (2005)

Publications

- "Interpretation of the Third Amendments to the Regulations on the Protection of New Plant Varieties ", Lexology, 2025
- "Examination Changes on Patents Relating to Biological and Chemical fields in Amendments to Guidelines for Patent Examination in 2025", Lexology, 2025
- "Crystal Form Patents Secure Maximum term PTE, Bringing a Major Shift to Pharmaceutical Patent Examination Landscape ", Lexology, 2026

Professional Membership

- AIPLA, Member of IP Practice in Europe & Patent Litigation Committee

Bar Admission

- Chinese Patent Bar (2015)
- Chinese Patent Agent Ad Litem (2019)

Languages

- Chinese
- English